Participants in the study will receive either eneboparatide or a placebo for a period of 24 weeks. The treatment is administered through a pre-filled pen for subcutaneous injection, which means it is injected under the skin. The goal is to evaluate how effective eneboparatide is in reducing the need for active vitamin D and oral calcium supplements, and in maintaining normal serum calcium levels. The study will also assess changes in symptoms and physical functioning of the participants.

In addition to eneboparatide, the study involves other medications such as calcitriol and calcium carbonate, which are commonly used to manage calcium levels. Another medication, alfacalcidol, is also part of the study. These medications are used to help understand the overall effectiveness of the new treatment. The study aims to provide valuable information on the safety and benefits of eneboparatide for people living with chronic hypoparathyroidism.

The purpose of the study is to find out whether taking magnesium aspartate by mouth for eight days can reduce the occurrence of long-term hypoparathyroidism six months after surgery. Participants will be randomly assigned to receive either the magnesium supplement or placebo, and neither the participants nor the doctors will know which treatment is being given. The magnesium or placebo will be taken starting before the surgery and continuing for several days afterward. During the study, doctors will monitor calcium levels and parathyroid hormone levels in the blood to check how well the parathyroid glands are working.

Throughout the study period, which lasts up to six months after surgery, participants will be checked at different time points to see if they develop hypoparathyroidism and whether they need additional treatments such as calcium or vitamin D supplements. The study will also track any side effects or unwanted reactions to the treatment and ask participants about symptoms they may experience related to low calcium levels. This information will help researchers understand if giving magnesium before and after thyroid surgery can protect the parathyroid glands and prevent complications.

Participants will be assigned to receive either palopegteriparatide, also known as TransCon PTH, through a subcutaneous injection, which is a small needle under the skin, or the standard treatment. The standard treatment consists of alfacalcidol, an active form of vitamin D, and calcium supplements taken orally. This study aims to observe how these different treatments affect daily life, thinking skills, and blood flow within the small vessels of the brain.

During the study, various assessments will be performed to monitor changes. This includes the use of MRI, a medical imaging technique that creates detailed pictures of the inside of the body, to look at the structure of the brain. The research also examines how blood moves through the capillaries, which are the tiny blood vessels that connect larger arteries and veins, to see if the treatment helps improve brain health and overall well-being.

The treatment being studied is palopegteriparatide, which is administered through subcutaneous injection. This means the medicine is delivered by injecting it into the fatty layer of tissue just under the skin using a pre-filled pen. Participants will receive this medication daily during the course of the study to see how it affects their ability to maintain healthy mineral levels without needing large amounts of supplemental vitamin D or high doses of calcium tablets.

The purpose of the study is to investigate how daily treatment with Indapamide for 14 days influences the amount of calcium excreted in the urine of patients with this condition. Participants will be randomly assigned to receive either Indapamide or a placebo. The study will last for a total of 14 days, during which changes in urinary calcium excretion will be monitored at both 7 and 14 days. Additionally, the study will observe changes in blood calcium levels and the need for supplements like active vitamin D and oral calcium.

Throughout the study, participants will follow a sodium-restricted diet to see how it affects calcium levels during the placebo period. The trial aims to provide valuable insights into the management of chronic post-surgical hypoparathyroidism and the potential benefits of using Indapamide as a treatment option. The findings could help improve the quality of life for individuals living with this condition by better managing their calcium levels.

The purpose of the study is to evaluate the safety, tolerability, and effectiveness of TransCon PTH in adults with hypoparathyroidism. Participants in the study will receive either TransCon PTH or a placebo. The study will begin with a period where participants are randomly assigned to receive either the treatment or placebo without knowing which one they are receiving. This is followed by an open-label extension, where all participants will have the opportunity to receive TransCon PTH. The study will monitor changes in calcium levels in the blood and urine, as well as the need for additional vitamin D and calcium supplements over a period of four weeks.

Throughout the study, participants will be required to perform daily injections of the study drug. The trial aims to determine if TransCon PTH can help maintain normal calcium levels without the need for additional supplements. The study will also assess the overall experience of using the treatment, including any side effects that may occur. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

The study aims to determine if using indocyanine green, a special dye that helps surgeons see blood vessels and tissues more clearly during surgery, can reduce the occurrence of low calcium levels after thyroid surgery. During the procedure, some patients will receive an injection of indocyanine green at a dose of up to 0.5 milligrams per kilogram of body weight, while others will undergo standard surgery without the dye.

The study will monitor patients’ calcium levels in their blood for up to 6 months after surgery. Doctors will check how well the parathyroid glands are working and whether patients develop any signs of low calcium levels. They will also track if using the dye helps surgeons better identify and preserve important structures during the operation.

During the trial, some patients will receive the Indocyanine Green dye, which is injected into the bloodstream. This dye helps highlight the blood vessels and the parathyroid glands during surgery, making it easier for surgeons to see and avoid damaging them. Other patients will undergo the surgery without the use of the dye. The study will compare the outcomes of these two groups to determine if the dye is effective in preserving the parathyroid glands. The trial will also monitor various health indicators, such as calcium and hormone levels, before and after the surgery, and follow up with patients for a year to check for any signs of hypoparathyroidism.

The study is designed to provide valuable information on whether using Indocyanine Green during thyroid surgery can improve patient outcomes by reducing the risk of complications related to the parathyroid glands. This research could potentially lead to better surgical techniques and improved quality of life for patients undergoing thyroid surgery.

The study involves comparing eneboparatide with a placebo to see how well it works over a period of 24 weeks. Participants will receive either the eneboparatide or the placebo through a pre-filled pen for injection under the skin. The goal is to determine if eneboparatide can help patients reduce their need for active vitamin D and oral calcium supplements, while maintaining normal calcium levels in the blood. Additionally, the study will assess changes in symptoms and physical functioning of the participants.

Other medications involved in the study include alfacalcidol, calcitriol, and calcium carbonate, which are commonly used to manage calcium levels in patients with hypoparathyroidism. The study will monitor the effects of eneboparatide on these medications and evaluate its overall impact on the participants’ health and quality of life. The trial is designed to provide valuable information on whether eneboparatide can be a beneficial treatment option for those living with chronic hypoparathyroidism.